CHEMED CORP
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
CHE$544.49+1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
|---|---|---|---|
| Chemed Corporation and Subsidiary Companies | |||
| (in thousands) | |||
| For the Years Ended December 31, | 2024 | 2023 | 2022 |
| Cash Flows from Operating Activities | |||
| Net income | $301,999 | $272,509 | $249,624 |
| Adjustments to reconcile net income to net cash provided by operations: | |||
| Depreciation and amortization | 63,049 | 60,865 | 59,172 |
| Stock option expense | 32,033 | 30,082 | 26,254 |
| Noncash portion of long-term incentive compensation | 18,794 | 9,267 | 6,188 |
| Litigation settlements | (5,750) | 2,050 | 4,000 |
| (Benefit)/provision for deferred income taxes | (4,138) | (8,027) | 14,827 |
| Noncash directors' compensation | 1,282 | 1,444 | 1,170 |
| Amortization of debt issuance costs | 321 | 580 | 342 |
| Deferred payroll taxes | - | - | (18,175) |
| Changes in operating assets and liabilities: | |||
| Decrease/(increase) in accounts receivable | 10,678 | (41,488) | (2,414) |
| Decrease/(increase) in inventories | 3,831 | (1,732) | (162) |
| Decrease in prepaid expenses | 4,237 | 87 | 2,397 |
| (Decrease)/increase in accounts payable and other current liabilities | (9,279) | (9,348) | 15,343 |
| Change in current income taxes | 2,182 | 11,748 | (996) |
| Net change in lease assets and liabilities | (674) | (1,424) | 1,471 |
| Increase in other assets | (25,591) | (9,952) | (45,779) |
| Increase/(decrease) in other liabilities | 22,749 | 12,802 | (3,350) |
| Other sources/(uses) | 1,774 | 836 | (26) |
| Net cash provided by operating activities | 417,497 | 330,299 | 309,886 |
| Cash Flows from Investing Activities | |||
| Business combinations, net of cash acquired | (97,400) | (3,994) | (3,529) |
| Capital expenditures | (49,531) | (56,854) | (57,325) |
| Proceeds from sale of fixed assets | 3,315 | 640 | 2,330 |
| Other uses | (295) | (434) | (878) |
| Net cash used by investing activities | (143,911) | (60,642) | (59,402) |
| Cash Flows from Financing Activities | |||
| Purchases of treasury stock | (361,389) | (67,697) | (114,515) |
| Proceeds from exercise of stock options | 56,517 | 102,192 | 44,968 |
| Dividends paid | (27,092) | (23,502) | (22,017) |
| Change in cash overdraft payable | (15,749) | 15,749 | (11,884) |
| Capital stock surrendered to pay taxes on stock-based compensation | (9,457) | (9,557) | (15,611) |
| Payments on other long-term debt | - | (97,500) | (2,500) |
| Proceeds from other long-term debt | - | - | 100,000 |
| Payments on revolving line of credit | - | - | (306,800) |
| Proceeds from revolving line of credit | - | - | 121,800 |
| Debt issuance costs | - | - | (1,586) |
| Other (uses)/sources | (2,024) | 490 | (1,108) |
| Net cash used by financing activities | (359,194) | (79,825) | (209,253) |
| (Decrease)/increase in cash and cash equivalents | (85,608) | 189,832 | 41,231 |
| Cash and cash equivalents at beginning of year | 263,958 | 74,126 | 32,895 |
| Cash and cash equivalents at end of year | $178,350 | $263,958 | $74,126 |
| The Notes to Consolidated Financial Statements are integral parts of these statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.